Tags

Type your tag names separated by a space and hit enter

Retrospective Analysis of the Effects of Non-Compliance with Denosumab on Changes in Bone Mineral Density During the COVID-19 Pandemic.
Patient Prefer Adherence. 2021; 15:1579-1584.PP

Abstract

Purpose

Although denosumab is a safe and effective treatment for osteoporosis in various clinical trials, few studies have investigated its efficacy in specific clinical situations. The effect of non-compliance with the standard six-month dosing regimen for denosumab on bone mineral density (BMD) was assessed in a retrospective study of patients prescribed denosumab during the COVID-19 pandemic.

Patients and Methods

Between February 2019 and September 2020, 638 patient records were reviewed, with 236 patients meeting the eligibility criteria. Patients were divided into three groups: those who received denosumab injections between five and seven months after their initial subcutaneous injection, those who received denosumab injections between seven and nine months after their initial subcutaneous injection, and those who received denosumab injections more than nine months after their initial subcutaneous injection. A multivariate regression study was conducted to compare the BMD shift (at least one year apart) before and after two denosumab injections between the three pre-specified groups in both the lumbar spine (LS) and the femoral neck (FN).

Results

The difference between LS BMD indicates that there is a statistical difference between subjects who received denosumab injections between 5 and 7 months (near-standard dosing interval) and more than 9 months (P=0.03), but not in FN BMD, and no clinically significant association was identified.

Conclusion

The results of this study show that in special clinical situations, such as the COVID-19 pandemic, clinicians may have some flexibility to prescribe denosumab, but the interval between injections should not exceed 9 months.

Authors+Show Affiliations

Department of Family Medicine, National Yang Ming Chiao Tung University Hospital, Yilan, Taiwan (Republic of China). Department of Biomedical Sciences, Chang Gung University, Taoyuan, Taiwan (Republic of China).Department of Biomedical Sciences, Chang Gung University, Taoyuan, Taiwan (Republic of China).Department of Leisure Services Management, Chaoyang University of Technology, Taichung, Taiwan (Republic of China).

Pub Type(s)

Journal Article

Language

eng

PubMed ID

34290494

Citation

Huang, Chun-Feng, et al. "Retrospective Analysis of the Effects of Non-Compliance With Denosumab On Changes in Bone Mineral Density During the COVID-19 Pandemic." Patient Preference and Adherence, vol. 15, 2021, pp. 1579-1584.
Huang CF, Shiao MS, Mao TY. Retrospective Analysis of the Effects of Non-Compliance with Denosumab on Changes in Bone Mineral Density During the COVID-19 Pandemic. Patient Prefer Adherence. 2021;15:1579-1584.
Huang, C. F., Shiao, M. S., & Mao, T. Y. (2021). Retrospective Analysis of the Effects of Non-Compliance with Denosumab on Changes in Bone Mineral Density During the COVID-19 Pandemic. Patient Preference and Adherence, 15, 1579-1584. https://doi.org/10.2147/PPA.S316144
Huang CF, Shiao MS, Mao TY. Retrospective Analysis of the Effects of Non-Compliance With Denosumab On Changes in Bone Mineral Density During the COVID-19 Pandemic. Patient Prefer Adherence. 2021;15:1579-1584. PubMed PMID: 34290494.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Retrospective Analysis of the Effects of Non-Compliance with Denosumab on Changes in Bone Mineral Density During the COVID-19 Pandemic. AU - Huang,Chun-Feng, AU - Shiao,Ming-Shi, AU - Mao,Tso-Yen, Y1 - 2021/07/15/ PY - 2021/04/16/received PY - 2021/07/08/accepted PY - 2021/7/22/entrez PY - 2021/7/23/pubmed PY - 2021/7/23/medline KW - COVID-19 KW - bone mineral density KW - compliance KW - denosumab KW - osteoporosis SP - 1579 EP - 1584 JF - Patient preference and adherence JO - Patient Prefer Adherence VL - 15 N2 - Purpose: Although denosumab is a safe and effective treatment for osteoporosis in various clinical trials, few studies have investigated its efficacy in specific clinical situations. The effect of non-compliance with the standard six-month dosing regimen for denosumab on bone mineral density (BMD) was assessed in a retrospective study of patients prescribed denosumab during the COVID-19 pandemic. Patients and Methods: Between February 2019 and September 2020, 638 patient records were reviewed, with 236 patients meeting the eligibility criteria. Patients were divided into three groups: those who received denosumab injections between five and seven months after their initial subcutaneous injection, those who received denosumab injections between seven and nine months after their initial subcutaneous injection, and those who received denosumab injections more than nine months after their initial subcutaneous injection. A multivariate regression study was conducted to compare the BMD shift (at least one year apart) before and after two denosumab injections between the three pre-specified groups in both the lumbar spine (LS) and the femoral neck (FN). Results: The difference between LS BMD indicates that there is a statistical difference between subjects who received denosumab injections between 5 and 7 months (near-standard dosing interval) and more than 9 months (P=0.03), but not in FN BMD, and no clinically significant association was identified. Conclusion: The results of this study show that in special clinical situations, such as the COVID-19 pandemic, clinicians may have some flexibility to prescribe denosumab, but the interval between injections should not exceed 9 months. SN - 1177-889X UR - https://www.unboundmedicine.com/medline/citation/34290494/Retrospective_Analysis_of_the_Effects_of_Non-Compliance_with_Denosumab_on_Changes_in_Bone_Mineral_Density_During_the_COVID-19_Pandemic. L2 - https://dx.doi.org/10.2147/PPA.S316144 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.